For patients with melanoma (15–17), gastric (18, 19) and liver cancer (20), gynecological (21, 22) and breast cancer (23, 24), and renal clear cell carcinoma (25), higher ICOS expression predicted much worse survival. This evidence concerns the gene ICOS and melanoma.